Susan Yost

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA.

Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company, based in Boston, MA, was founded in 1954. Servier Pharmaceuticals is committed to innovation and improving the lives of patients, their families, and caregivers. The company invests in research and development to address the unmet needs of patients, particularly in the areas of oncology, cardiovascular diseases, cancers, diabetes, immuno-inflammatory, and neuro-psychiatric diseases. The company offers financial assistance to support patients, advocacy groups, and healthcare professionals. The company strives for transparency in clinical trials and research and development. Servier Pharmaceuticals aims to create a brighter future for all by providing life-saving treatments to a greater number of patients. The company actively seeks alliances, acquisitions, licensing deals, and partnerships to accelerate access to therapies. David K. Lee has been the CEO of the company since 2018.

Deerfield Management Co. LP (Private Equity) (Deerfield) is a private equity subsidiary of Deerfield Management Co. LP founded in 1994. The firm is headquartered in the New York.

Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded in March 1991 and is headquartered in Pleasanton, CA.

Pairwise Plants LLC operates as a agriculture company. The company was founded by Feng Zhang, David Liu and J. Keith Joung and is headquartered in Durham, NC.

Neomorph, Inc. is an American venture-backed biotechnology company that focuses on discovering innovative new medicines against 'undruggable' targets to solve critical problems in human health. The company is headquartered in an undisclosed location and has a key collaboration with the Center for Protein Degradation at the Dana Farber Cancer Institute. Neomorph's team is comprised of industry-leading experts in protein degradation and molecular glues who are committed to advancing the science and technology of molecular glue drug discovery. The company's patient-first, science-driven approach is complemented by its dedication to a supportive and collaborative work environment. Neomorph was founded by Eric Fischer, Philip Chamberlain, Scott A. Armstrong, and Benjamin Ebert, with Philip Chamberlain serving as the CEO since incorporation.

Janus Henderson Investors US LLC (JHIUS) is a SEC-registered investment advisor and mutual fund manager headquartered in Denver, Colorado. The firm was founded in 1969 and formerly known as Janus Capital Management LLC. They are a subsidiary of Janus Henderson US (Holdings) Inc., owned by Janus Henderson Group plc (NYSE: JHG, LSE: 0RPW) in Great Britain. JHIUS provides investment management services, as an investment adviser or sub-adviser, to pooled investment vehicles.

Dracen Pharmaceuticals, Inc. develops immuno-metabolism drugs. The company was founded by Barbara Slusher, Jonathan D. Powell, Pavel Majer, and Rana Rais and is headquartered in New York, NY.

Vescor LLC, engages in the discovery and development autophagy targeted therapeutics for cancer treatment. The firm develops small molecule inhibitors of a number of protein targets at critical nodes of the autophagy cascade, perform investigational new drug (IND) enabling studies, and move these into clinical development. The company was founded by Eileen White and Alec Kimmelman and is headquartered in New York, NY.

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.

Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

MTrap, Inc. engages in the development of novel therapeutic devices that interfere with the intense dialogue and crosstalk between the primary tumor and the microenvironment and represent a new disruptive approach to cancer treatment. The company was founded by Maybelle L. Jordan and is headquartered in Huntington, NY.

Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA.

Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA.

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

Vibliome Therapeutics LLC develops therapeutics for the treatment of cancer, contraception and other indications. The company was founded by Gary Flynn in 2017 and is headquartered in Bozeman, MT.

AlivaMab Discovery Services LLC is a private company that specializes in generating and screening large panels of antibodies to achieve their partners' design goals. AlivaMab Discovery Services is based in San Diego, CA. The company focuses on delivering antibodies that are characterized for function, kinetics, and developability, and engineering for advanced modalities, including multispecifics and cars. The company has experience in antibody drug discovery and development from many of the world's top pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech. The company was founded by John Lippincott, and the CEO is Larry L. Green.